Autoantibodies occur in many different nervous system disorders, and are increasingly being found in disorders not traditionally associated with the immune system. Determining if the autoantibodies play a functional or pathogenic role is critical in selecting the most appropriate treatment options.
Browsing: Demyelinating disease
This article examines a number of different disease-modifying therapy strategies for the treatment of relapsing-remitting multiple sclerosis.
A researcher’s own experiences have led to further understanding of the repair process needed for multiple sclerosis.
The latest update on the potential accumulation of gadolinium in brain tissue from gadolinium-based contrast agents
In this interview, Dr Akassoglou discusses her pioneering research, as well as the key challenges in this exciting area of neuroscience and her hopes for the field.
Dr Paul Gallagher (Institute of Neurological Sciences, Glasgow, UK) provides an overview of these two recent papers by Jokubaitis and colleagues  and Cree and colleagues, which both assessed factors predictive of long-term disability outcomes in people with multiple sclerosis (MS).
Autologous hematopoietic stem cell transplantation prevented symptoms of severe MS from worsening for 5 years in 46% of patients in a recent clinical trial.
Lauren Pulling highlights some of the key trending topics in neurology and neuroscience from 2016, as well as the top read articles of the year – take a look and let us know your thoughts.
Researchers have demonstrated that deposits caused by repeated use of linear contrast agents in MRI scans could be reduced by utilizing alternative agents in multiple sclerosis patients.